Oncternal Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Oncternal's estimated annual revenue is currently $4.5M per year.(i)
  • Oncternal's estimated revenue per employee is $112,000

Employee Data

  • Oncternal has 40 Employees.(i)
  • Oncternal grew their employee count by 0% last year.

Oncternal's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
2
Head Information TechnologyReveal Email/Phone
3
Head Biometrics & Data SciencesReveal Email/Phone
4
General Counsel & Corporate SecretaryReveal Email/Phone
5
Head Regulatory AffairsReveal Email/Phone
6
SVP, HRReveal Email/Phone
7
General CounselReveal Email/Phone
8
SVP, Corporate DevelopmentReveal Email/Phone
9
VP, Clinical DevelopmentReveal Email/Phone
10
Chief Medical OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$212.8M10635%$65MN/A
#2
$35.6M2316%N/AN/A
#3
$45M299-4%$102.6MN/A
#4
$3.2M30-25%$21.3MN/A
#5
$34M2260%$42.9MN/A
#6
$3.6M34-28%$35MN/A
#7
$0.8M10N/AN/AN/A
#8
$12.6M90-9%N/AN/A
#9
$17.4M1240%$96.4MN/A
#10
$5.2M49-25%$75.6MN/A
Add Company

What Is Oncternal?

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.

keywords:N/A

N/A

Total Funding

40

Number of Employees

$4.5M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Oncternal News

2022-04-13 - Oncternal Therapeutics Deprioritizes Development of ONCT ...

Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle...

2022-04-06 - Oncternal Therapeutics Deprioritizes ONCT-216 Development

Oncternal Therapeutics Inc. said it has deprioritized development of its potential Ewing sarcoma treatment, ONCT-216, to reallocate...

2022-04-06 - Oncternal deprioritizes development of ONCT-216, to focus on ...

Oncternal will reallocate resources to its global phase 3 study of its investigational anti-ROR1 monoclonal antibody zilovertamab for the...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.1M40-7%N/A
#2
$4.6M40-13%N/A
#3
$4.6M400%N/A
#4
$4.6M40N/AN/A
#5
$9.9M400%$10.8M